• Oxford Cancer Biomarkers,Ltd.(OCB)
    Oxford Cancer Biomarkers,Ltd.(OCB)

    Oxford Cancer Biomarkers translates ground-breaking scientific discovery into predictive biomarker diagnostic products that allow medicines to be personalised for the benefit of the cancer patient.  Oxford Cancer Biomarkers is a spin-out of the University of Oxford and has strong links with the Medical Sciences Division in Oxford University.  The company was founded by Nick La Thangue, Ph.D., Chair of Cancer Biology at Oxford University and David Kerr, CBE, D.Sc., M.D. FMedSci, Professor of Cancer Medicine at Oxford University. Investors in OCB include Longwall Venture Partners LLP, Esperante BV and the University.

    MBM is a strategic partner of OCB in China, introducing ColoPredict, ColoProg, ColoTox, undertaking further development and commercialization in China. Meanwhile, OCB will continue to introduce other accurate diagnostic test landing in China through MBM.

  • 20 / 20 Genesystems
    20 / 20 Genesystems

    20/20 GeneSystems (“20/20”) was founded to develop and promote an innovative proteomics product line that provides drug companies, bio-defense specialists and life scientists with new tools for protein analysis. Headquarters are in the heart of the biotechnology corridor in Rockville, Maryland, in close proximity to the National Institutes of Health with which we have extensive collaborations. 20/20 GeneSystems is a diagnostics company positioned at the crossroads of traditional tumor biomarkers and algorithms powered by Big Data Analytics

    MBM is a strategic partner of 20/20 in China, introducing Lung  Cancer Test , undertaking further development and commercialization in China.

  • XCellCure, LLC.(XC)
    XCellCure, LLC.(XC)

    A Biotech Corp in Saint Louis, USA, focuses on innovative heart monitoring. AMiAware, an early warning product of XC, offers 13 levels of innovative biomarkers that provide a risk stratification for the risk of myocardial infarction and prevent a potentially fatal heart attack. Current clinical detection methods and algorithms are not able to predict the next 24 or 72 hours of possible myocardial infarction. AMiAware has the ability to make an early warning before the onset of myocardial infarction from 48 hours to 6 months.

    MBM is a strategic partner of XC in China. MBM will be responsible for AMiAware related LDT, kit, POCT equipment for China's certification and registration, as well as commercial transformation.

  • Veritas Genetics Biotechnology Co., Ltd.
    Veritas Genetics Biotechnology Co., Ltd.

    Veritas Genetics was founded by genomics experts from the Harvard University School of Medicine. One of the founders, George Church, a professor at Harvard University School of medicine and MIT, and a founding member of the Wyss Institute of bioengineering, has been regarded as a pioneer in the field of genomics. Veritas Genetics has the Practice License of Medical Institution of The People's Republic of China, and also accredited by CAP and CLIA. Veritas Genetics' gene testing covers whole genome, whole exon group, and whole transcriptome. supporting clinical, and also providing scientific research cooperation.

    MBM docks clinical research needs for Veritas Genetics, and explores the feasibility of commercial applications.

A total of 1/2 Pages